The Vitamin D Absorption Glitch

The Mechanism of Action

Vitamin D is not technically a vitamin — it is a seco-steroid pro-hormone produced in the skin under UVB exposure (or consumed from diet/supplements as cholecalciferol, D3). To become biologically active (calcitriol, 1,25-dihydroxyvitamin D), it must undergo two sequential hydroxylations:

Hepatic 25-hydroxylation (by CYP2R1): Converts D3 → calcidiol (25(OH)D) — the form measured by standard serum tests
Renal 1α-hydroxylation (by CYP27B1): Converts calcidiol → calcitriol — the biologically active steroid hormone

All enzymes that metabolise vitamin D appear to require magnesium as a co-factor in the enzymatic reactions in the liver and kidneys. Without sufficient intracellular magnesium, neither conversion step proceeds efficiently — leaving D3 stored in its inactive form regardless of how much is consumed or what the serum 25(OH)D reading shows. This is the biological “glitch” responsible for supplement resistance: serum 25(OH)D may appear adequate while cellular activation remains impaired.

The mechanistic logic extends further: activated calcitriol also increases intestinal absorption of magnesium via TRPM6/TRPM7 channels, creating a bidirectional dependency. Magnesium is required to activate D3; D3 helps maintain magnesium homeostasis. When either is deficient, the other becomes functionally less available.

The Magnesium Depletion Risk

When large doses of D3 are supplemented, the liver and kidneys accelerate CYP enzyme activity to process the influx. Since these enzymes are magnesium-dependent, high-dose D3 supplementation can increase magnesium utilisation — potentially unmasking or worsening a pre-existing subclinical deficiency.

Forge Note — Evidence Grading: The magnesium depletion concern is mechanistically well-grounded and supported by observational data (Dai et al., AJCN, 2012, showing the relationship between magnesium status and vitamin D metabolism in NHANES). It should not be described as confirmed by “2026 longitudinal studies” — no such studies exist. The mechanism is real; the population-level risk of acute depletion from supplementation is plausible but not definitively quantified. Conservative supplementation co-administration is the appropriate precautionary response.

Common presentations of functional magnesium insufficiency that may be unmasked or worsened by high-dose D3 include:

Muscle hyper-excitability: Cramps, twitching, or tremors (reduced magnesium at the neuromuscular junction)
Autonomic friction: Heart palpitations or anxiety (magnesium’s role as an endogenous calcium channel regulator)
Sleep disruption: Impaired GABAergic inhibitory tone that down-regulates the CNS for sleep initiation and maintenance

If these symptoms emerge or worsen after starting D3 supplementation, magnesium co-administration is the first corrective intervention.

The Forge Protocol: The Activation Stack

01. The Catalyst — Vitamin D3

Dosage: 2,000–5,000 IU daily (test-and-correct approach; see Audit section).

Logic: D3 is fat-soluble — absorption is significantly reduced without a lipid carrier. Take with a meal containing at least 15g of dietary fat. Olive oil, avocado, eggs, and nuts are all adequate carriers. Studies confirm D3 absorption increases approximately 50% when taken with a fat-containing meal versus a fat-free meal.

Forge Note on Dosing: The original article recommended 5,000 IU as a standard daily dose. This is at the upper end of evidence-based supplementation and should be personalised based on baseline 25(OH)D. The 2024 Endocrine Society guideline found insufficient evidence to determine specific blood-level thresholds for 25(OH)D for adequacy or disease prevention in healthy adults under 75. The practical Forge position: start at 2,000 IU, test 25(OH)D at 3 months, and adjust to target the 40–60 ng/mL range. Individuals starting from deficiency (<20 ng/mL) may require 5,000 IU during a correction phase before dropping to a maintenance dose.

02. The Co-Factor — Magnesium

Dosage: 200–400mg elemental magnesium daily (form-dependent — see below).

Logic: Magnesium is an essential co-factor for vitamin D synthesis and activation and, in turn, can increase intestinal absorption of magnesium, establishing a feed-forward loop to maintain its homeostasis. The Forge prioritises magnesium bisglycinate for its superior tolerability and absorption profile versus magnesium oxide (the cheapest and least bioavailable form, which primarily acts as a laxative at higher doses).

Forge Correction — Blood-Brain Barrier Claim: The original article stated that magnesium bisglycinate “crosses the blood-brain barrier, supporting Neural Resilience.” This claim is not established for bisglycinate specifically. The magnesium form with the most evidence for CNS penetration is magnesium L-threonate (magtein), which has been specifically studied for its ability to increase cerebrospinal fluid magnesium concentrations and hippocampal synaptic density in animal models, with some human cognitive trial data. If CNS magnesium delivery is the specific goal, L-threonate is the evidence-supported form. For the D3 co-factor role specifically, bisglycinate and glycinate are the preferred forms for their bioavailability and gastrointestinal tolerance.

03. The Traffic Controller — Vitamin K2 (MK-7)

Dosage: 100–200 mcg daily, taken with the fat-containing meal alongside D3.

Logic: D3 upregulates intestinal calcium absorption (from approximately 10–15% to 30–40% of dietary calcium). This calcium must be correctly directed — to bone matrix rather than arterial walls. Vitamin K2 (as MK-7, the long-acting menaquinone form) activates two calcium-routing proteins:

Osteocalcin: Binds calcium into hydroxyapatite within bone matrix
Matrix Gla Protein (MGP): The primary inhibitor of arterial calcification — must be K2-carboxylated to function; K2 deficiency leaves MGP inactive, allowing calcium to deposit in arterial walls

The Rotterdam Study (n=4,807) found that the highest dietary menaquinone (K2) intake was associated with 52% lower aortic calcification and 57% lower aortic calcification-associated mortality. As detailed in the Vascular Age Briefing, this is the mechanistic bridge between the Vitamin D protocol and Pillar 02 (Physical Architecture) — high-dose D3 without K2 in an individual with subclinical arterial calcification risk may worsen the calcification process rather than improving overall health.

Forge Note: K2 MK-7 (longer half-life, better tissue distribution) is preferred over MK-4 for a once-daily supplementation protocol. MK-4 has a half-life of approximately 1–2 hours and requires multiple daily doses to maintain effective serum levels; MK-7 has a half-life of 72 hours and sustains protective K2 activity throughout the day from a single dose.

Actionable Resilience: The Audit

Baseline and 3-Month Serum Test: Measure 25(OH)D at baseline before starting supplementation, and again at 3 months to assess response and adjust dose. Testing the wrong form — 1,25(OH)₂D (calcitriol, the active form) — is a common clinical error; this form is tightly regulated and may appear normal even when calcidiol stores are depleted. Always specify 25(OH)D.
Magnesium Status — Use RBC Magnesium, Not Serum: Standard serum magnesium tests are largely uninformative for intracellular status — the body maintains serum magnesium in a narrow range by drawing from bone and muscle reserves even as intracellular stores deplete. RBC (Red Blood Cell) magnesium reflects actual intracellular status with substantially greater accuracy. A result below 5.2–5.6 mg/dL on RBC magnesium warrants intervention regardless of serum magnesium appearing normal.
The Forge Target Range — 40–60 ng/mL: This range is derived from the dose-response meta-analysis literature (lowest risk for most outcomes at 40–100 nmol/L, equivalent to approximately 16–40 ng/mL in some analyses; Forge targets the upper half of this range for a longevity-optimisation context). The 2024 Endocrine Society guideline explicitly states it could not determine specific blood-level thresholds for 25(OH)D for disease prevention benefits, which should be understood as an honest acknowledgement of the limitations of RCT data rather than a statement that levels don’t matter. The Forge’s 40–60 ng/mL position is based on the association literature and the mechanistic logic of ensuring adequate substrate for CYP enzyme activation across all target tissues. Levels above 100 ng/mL carry risk of hypercalcaemia and should not be targeted.
Homocysteine as an Indirect Methyl Cycle Signal: Elevated homocysteine (>10 µmol/L) often co-occurs with vitamin D insufficiency and indicates that the one-carbon metabolism cycle is under strain — affecting both methylation (DNA Methylation article) and magnesium co-factor efficiency. The D3/Mg stack and homocysteine status are interconnected; an elevated homocysteine in an individual starting D3 supplementation warrants adding B-complex support to the protocol as well.

Clinical Citations

Uwitonze A.M. & Razzaque M.S., Journal of the American Osteopathic Association (2018): “Role of Magnesium in Vitamin D Activation and Function.” Vol. 118(3), pp. 181–189. All enzymes that metabolise vitamin D require magnesium as a co-factor in the enzymatic reactions in the liver and kidneys; magnesium is an essential co-factor for vitamin D synthesis and activation, and in turn D3 increases intestinal magnesium absorption, establishing a feed-forward homeostatic loop. DOI: 10.7556/jaoa.2018.037 (Note: the original article described this as a “2025 update” — the paper was published in 2018; no 2025 revision exists under this title.)
Rosanoff A., Dai Q. & Shapses S.A., Advances in Nutrition (2016): “Essential Nutrient Interactions: Does Low or Suboptimal Magnesium Status Interact with Vitamin D and/or Calcium Status?” Vol. 7(1), pp. 25–43. Magnesium insufficiency independently and additively impairs vitamin D metabolism and calcium homeostasis; the nutritional triad framework. DOI: 10.3945/an.115.008631
Demay M.B. et al. (Endocrine Society), Journal of Clinical Endocrinology & Metabolism (2024): “Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline.” Updated clinical guidance; panel found insufficient RCT evidence to establish specific serum 25(OH)D thresholds for disease prevention in healthy adults; recommends against routine supplementation above RDI or routine testing in healthy adults under 75 without established indications. DOI: 10.1210/clinem/dgae290
Geleijnse J.M. et al., Rotterdam Study (2004): High dietary menaquinone (K2) intake associated with 52% lower aortic calcification severity and 57% lower aortic calcification-associated mortality (n=4,807). DOI: 10.1093/jn/134.11.3100
Dai Q. et al., American Journal of Clinical Nutrition (2012): “Magnesium status and supplementation influence vitamin D status and metabolism.” NHANES observational analysis confirming the relationship between magnesium status and efficient vitamin D 25-hydroxylation and 1α-hydroxylation. DOI: 10.3945/ajcn.111.030924